Joe Wiley, Amryt CEO

Am­ryt earns a pri­or­i­ty re­view in a rare dis­ease that makes pa­tients' skin frag­ile as but­ter­fly wings

A year af­ter flash­ing mixed Phase III da­ta, an Irish drug­mak­er no­to­ri­ous for own­ing some of the coun­try’s most ex­pen­sive drugs is get­ting an ex­pe­dit­ed look at its treat­ment for epi­der­mol­y­sis bul­losa (EB) — a rare dis­ease where a pa­tient’s skin be­comes as frag­ile as but­ter­fly wings.

The FDA grant­ed pri­or­i­ty re­view to Am­ryt’s Oleogel-S10, ac­cel­er­at­ing the drug’s as­sess­ment time from 10 months to six months, the com­pa­ny said on Thurs­day. The agency set its PDU­FA date for Nov. 30, and CEO Joe Wi­ley said launch plans are “well ad­vanced.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.